4-iodo-1,3,5-trihydroxybenzene | 134810-54-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-iodo-1,3,5-trihydroxybenzene
• 英文别名: iodophloroglucidol；iodophloroglucinol；2-iodobenzene-1,3,5-triol
• CAS: 134810-54-1
• 化学式: C₆H₅IO₃
• 分子量: 252.008
• InChiKey: KKANESHTPHPCDC-UHFFFAOYSA-N

物化性质

• 熔点：
  162-164 °C (decomp)
• 沸点：
  300.7±22.0 °C(Predicted)
• 密度：
  2.359±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-iodo-1,3,5-trihydroxybenzene 在 镍 盐酸 、 氢气 、 硼酸 、 溶剂黄146 、 palladium dichloride 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 生成 木犀草素
  参考文献：
  名称：

  Ellemose, Steen; Kure, Niels; Torsell, Kurt B. G., Acta Chemica Scandinavica, 1995, vol. 49, # 7, p. 524 - 529

  摘要：

  DOI：
• 作为产物：
  描述：

  间苯三酚 以87%的产率得到
  参考文献：
  名称：

  THOMSEN, IB;TORSSELL, KURT B. G., ACTA CHEM. SCAND., 45,(1991) N, C. 539-542

  摘要：

  DOI：

文献信息

• NOVEL LUMINESCENT LANTHANIDE CHELATES WITH ENHANCED EXCITATION PROPERTIES
  申请人：DHR Finland OY

  公开号：US20130183771A1

  公开（公告）日：2013-07-18

  The present application discloses a luminescent lanthanide chelate comprising one or more chromophoric moieties of the formula (I) or of the formula (III) wherein R 1 , R 2 and R 2* each independently are selected from carbon-containing substituents forming a C—O bond with the neighbouring oxygen atom, R 3 and R 4 each represent a bond between the chromophoric moiety and other moieties of the chelate, and Ln 3+ is a lanthanide ion, as well as the corresponding luminescence lanthanide chelating ligand. The application also discloses a detectable molecule comprising a biospecific binding reactant (such as an antibody) conjugated to the luminescent lanthanide chelate as well as a method of carrying out a biospecific binding assay, the use of such a detectable molecule in a specific bioaffinity based binding assay utilizing time-resolved fluorometric determination of a specific luminescence, and a solid support material conjugated with the luminescent lanthanide chelate.

  本申请公开了一种发光镧系螯合物，包括一个或多个具有以下式(I)或式(III)的色团基团，其中R1、R2和R2*各自独立地选自与相邻氧原子形成C—O键的含碳取代基，R3和R4分别代表色团基团与螯合物的其他基团之间的键，Ln3+是镧系离子，以及相应的发光镧系螯合配体。该申请还公开了一种可检测的分子，包括与发光镧系螯合物结合的生物特异性结合试剂（如抗体），以及进行生物特异性结合测定的方法，利用这种可检测的分子在利用时间分辨荧光确定特定发光的特定生物亲和性结合测定中的应用，以及与发光镧系螯合物结合的固体支持材料。
• Luminescent Lanthanide Chelates Having Three Chromophores and Their Use
  申请人：Meltola Niko

  公开号：US20130210165A1

  公开（公告）日：2013-08-15

  The present application discloses a luminescent lanthanide chelate of formula (I) with lanthanides such as europium, as well as the corresponding luminescence lanthanide chelating ligand. The application also discloses a detectable molecule comprising a biospecific binding reactant (such as an antibody) conjugated to the luminescent lanthanide chelate as well as a method of carrying out a biospecific binding assay, the use of such a detectable molecule in a specific bioaffinity based binding assay utilizing time-resolved fluorometric determination of a specific luminescence, and a solid support material conjugated with the luminescent lanthanide chelate.

  本申请公开了一种具有镧系元素（如铕）的荧光配合物(I)的配合物，以及相应的荧光镧系螯合配体。该申请还公开了一种检测分子，包括与荧光镧系配合物偶联的生物特异性结合反应物（如抗体），以及进行生物特异性结合测定的方法，使用这种检测分子在利用时间分辨荧光测定特定荧光的特定生物亲和性基础结合测定中，以及与荧光镧系螯合物偶联的固体支持材料的使用。
• Anti-Mycobacterial Activity of Flavonoid and Pyrimidine Compounds
  作者：Saurabh Garg、Rakesh Kumar、Dennis Kunimoto、Gina R. Rayat

  DOI：10.3390/molecules27196714

  日期：——

  We evaluated the anti-mycobacterial effect of a flavonoid 5,7-dihydroxy-2-(4-hydroxyphenyl) 4H-chromen-4-one (1) and two pyrimidines, 4-hydroxy-2-dimethylamino-5-nitroso-6-aminopyrimidine (2) and 2-chloro-5-n-nonylpyrimidine (3) in vitro against Mycobacterium tuberculosis (M. tuberculosis, H37Ra) and Mycobacterium avium (M. avium), using a Microplate Alamar Blue Assay (MABA). The effects of the compounds 1–3 in combination with first- and second-line anti-TB drugs isoniazid, rifampicin, cycloserine, and clarithromycin on the growth of M. tuberculosis and M. avium were also evaluated in in vitro assays. As a single agent, compounds 1 and 2 exhibited modest activity while compound 3 was the most effective against M. tuberculosis and M. avium. When compounds 1–3 were evaluated at lower than 50% of their inhibitory concentrations in a two-drug combination with isoniazid or rifampicin, they showed additive to synergistic interactions. This inhibitory effect was improved when each of the three compounds was tested together in a three-drug combination with two of the first-line anti-TB drugs. Compounds 1–3 also demonstrated strong synergistic interaction in combination with cycloserine and clarithromycin in inhibiting the growth of M. tuberculosis and M. avium, respectively. This study demonstrated that compounds 1–3 have potential to be developed as effective anti-TB agents with combined use.

  我们采用微孔板阿拉玛蓝分析法（MABA）评估了一种黄酮类化合物 5,7-二羟基-2-（4-羟基苯基）4H-色烯-4-酮（1）和两种嘧啶类化合物 4-羟基-2-二甲氨基-5-亚硝基-6-氨基嘧啶（2）和 2-氯-5-壬基嘧啶（3）在体外对结核分枝杆菌（M.结核分枝杆菌（M. tuberculosis，H37Ra）和鸟分枝杆菌（M. avium）的体外试验。）在体外试验中，还评估了化合物 1-3 与一线和二线抗结核药物异烟肼、利福平、环丝氨酸和克拉霉素联用对结核分枝杆菌和鸟疫分枝杆菌生长的影响。作为单剂，化合物 1 和 2 表现出适度的活性，而化合物 3 对结核杆菌和阿维菌素最有效。当化合物 1-3 与异烟肼或利福平以低于 50%的抑制浓度进行两药联用评估时，它们显示出相加到协同的相互作用。在与两种一线抗结核药物进行三药联合试验时，这三种化合物的抑制效果都得到了改善。化合物 1-3 在与环丝氨酸和克拉霉素联用时，也分别在抑制结核杆菌和阿维菌素的生长方面表现出很强的协同作用。这项研究表明，化合物 1-3 有潜力开发成联合使用的有效抗结核药物。
• Gothelf, Kurt V.; Torssell, Kurt B. G., Acta Chemica Scandinavica, 1994, vol. 48, # 1, p. 61 - 67
  作者：Gothelf, Kurt V.、Torssell, Kurt B. G.

  DOI：——

  日期：——
• Gothelf, Kurt; Thomsen, Ib; Torssell, Kurt B. G., Acta Chemica Scandinavica, 1992, vol. 46, # 5, p. 494 - 495
  作者：Gothelf, Kurt、Thomsen, Ib、Torssell, Kurt B. G.

  DOI：——

  日期：——